1.Dermoscopic Findings in Onychomycosis.
Korean Journal of Medical Mycology 2017;22(1):50-51
No abstract available.
Dermoscopy
;
Mycoses
;
Onychomycosis*
2.Onychopapilloma Presenting as Erythronychia and Leukonychia: Dermoscopic Features of Two Cases in Korea.
Minsoo KIM ; Gwanghyun JO ; Cheol LEE ; Je Ho MUN
Annals of Dermatology 2018;30(6):742-744
No abstract available.
Korea*
3.Pigmented Onychomatricoma Showing a Longitudinal Melanonychia: A Case Report and Brief Review of Literature.
Sung Cheol JUNG ; Tae Min LEE ; Minsoo KIM ; Gwanghyun JO ; Je Ho MUN
Annals of Dermatology 2018;30(5):637-639
No abstract available.
Nail Diseases
;
Nails, Malformed
;
Melanoma
;
Skin Neoplasms
4.A Case of Acutely Developed Ischemic Fasciitis Caused by Surgical Positioning.
Jungyoon MOON ; Gwanghyun JO ; Hyun sun PARK ; Hyun Sun YOON ; Soyun CHO
Korean Journal of Dermatology 2018;56(4):298-300
No abstract available.
Fasciitis*
;
Fibroblasts
;
Ischemia
5.Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea.
Chong Won CHOI ; Seungkeol YANG ; Gwanghyun JO ; Bo Ri KIM ; Sang Woong YOUN
Annals of Dermatology 2018;30(6):668-675
BACKGROUND: Drug survival, defined as the time until discontinuation, is a parameter reflecting real-world therapeutic effectiveness. Few studies have examined the influence of economic factors on the drug survival of biologic agents for psoriasis, particularly in Asian countries. OBJECTIVE: To determine the drug survival for ustekinumab in real-life settings and investigate the factors affecting drug survival for psoriasis patients in Korea. METHODS: We evaluated 98 psoriasis patients who were treated with ustekinumab at a single center. We analyzed the efficacy and drug survival of ustekinumab. Cox proportional hazard analysis and competing risk regression analysis were performed to reveal the factors affecting the drug survival of ustekinumab. RESULTS: The overall mean drug survival was 1,596 days (95% confidence interval [CI], 904~2,288). Among the 39 cessations of ustekinumab treatment, 9 (23.1%) patients discontinued treatment after experiencing satisfactory results. Multivariate Cox proportional hazard analysis revealed that paying on patients' own expense was the major predictor for the discontinuation of ustekinumab (hazard ratio [HR], 9.696; 95% CI, 4.088~22.998). Competing risk regression analysis modeling of discontinuation because of factors other than satisfaction of an event also revealed that ustekinumab treatment at the patient's expense (HR, 4.138; 95% CI, 1.684~10.168) was a predictor of discontinuation rather than satisfaction. CONCLUSION: The results of our study revealed that the cost of biologics treatment affects the drug survival of ustekinumab and suggested that economic factors affect the drug survival of ustekinumab treatment in Korea.
Asian Continental Ancestry Group
;
Biological Factors
;
Biological Products
;
Costs and Cost Analysis
;
Humans
;
Korea*
;
Psoriasis*
;
Ustekinumab*
Result Analysis
Print
Save
E-mail